Phillip Darcy

List of Publications by Year
in descending order

153 papers	14,866 citations	18482 62 h-index	19749 117 g-index
154 all docs	154 docs citations	154 times ranked	20982 citing authors

#	Article	IF	Citations
1	PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. Cancer Discovery, 2022, 12, 752-773.	9.4	52
2	Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors. Molecular and Cellular Biology, 2022, 42, MCB0044921.	2.3	8
3	Differential location of NKT and MAIT cells within lymphoid tissue. Scientific Reports, 2022, 12, 4034.	3.3	2
4	Crossâ€talk between tumors at anatomically distinct sites. FEBS Journal, 2021, 288, 81-90.	4.7	9
5	Generating CAR T cells from tumor-infiltrating lymphocytes. , 2021, 9, 251513552110171.	2.3	6
6	Cellular networks controlling T cell persistence in adoptive cell therapy. Nature Reviews Immunology, 2021, 21, 769-784.	22.7	83
7	CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nature Communications, 2021, 12, 3236.	12.8	99
8	Myeloma natural killer cells are exhausted and have impaired regulation of activation. Haematologica, 2021, 106, 2522-2526.	3.5	8
9	MAIT cells regulate NK cell-mediated tumor immunity. Nature Communications, 2021, 12, 4746.	12.8	45
10	A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 6222-6234.	7.0	17
11	Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma. Cancers, 2021, 13, 4704.	3.7	9
12	Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. Cancer Immunology, Immunotherapy, 2021, 70, 1811-1820.	4.2	11
13	Adoptive transfer of tumor-specific Th9 cells eradicates heterogeneous antigen-expressing tumor cells. Cancer Cell, 2021, 39, 1564-1566.	16.8	5
14	Augmenting Adoptive T-cell Immunotherapy by Targeting the PD-1/PD-L1 Axis. Cancer Research, 2021, 81, 5803-5805.	0.9	4
15	<scp>PTPN</scp> 2 phosphatase deletion in T cells promotes antiâ€tumour immunity and <scp>CAR</scp> Tâ€cell efficacy in solid tumours. EMBO Journal, 2020, 39, e103637.	7.8	79
16	Enhancing chimeric antigen receptor Tâ€cell immunotherapy against cancer using a nanoemulsionâ€based vaccine targeting crossâ€presenting dendritic cells. Clinical and Translational Immunology, 2020, 9, e1157.	3.8	23
17	IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. Molecular Therapy, 2020, 28, 2379-2393.	8.2	49
18	Pharmacological and genetic strategies for targeting adenosine to enhance adoptive T cell therapy of cancer. Current Opinion in Pharmacology, 2020, 53, 91-97.	3.5	5

#	Article	IF	Citations
19	Primary and metastatic breast tumors cross-talk to influence immunotherapy responses. OncoImmunology, 2020, 9, 1802979.	4.6	5
20	Chimeric antigen receptor T cell therapies for thoracic cancersâ€" challenges and opportunities. Journal of Thoracic Disease, 2020, 12, 4510-4515.	1.4	1
21	Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nature Immunology, 2020, 21, 914-926.	14.5	114
22	p38 Kinase: A Key Target for Driving Potent T Cells for Adoptive Immunotherapy. Cancer Cell, 2020, 37, 756-758.	16.8	3
23	High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. , 2020, 8, e000792.		45
24	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clinical Cancer Research, 2020, 26, 487-504.	7.0	355
25	Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses. Journal of Thoracic Disease, 2020, 12, 4504-4509.	1.4	3
26	A New Safety Approach Allowing Reversible Control of CAR T Cell Responses. Molecular Therapy, 2020, 28, 1563-1566.	8.2	0
27	Supercharging adoptive T cell therapy to overcome solid tumorâ€"induced immunosuppression. Science Translational Medicine, 2019, 11, .	12.4	100
28	Enterotoxins can support CAR T cells against solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25229-25235.	7.1	16
29	Antagonism of IAPs Enhances CAR T-cell Efficacy. Cancer Immunology Research, 2019, 7, 183-192.	3.4	68
30	Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. Scientific Reports, 2018, 8, 4159.	3.3	79
31	Targeting Adenosine Receptor Signaling in Cancer Immunotherapy. International Journal of Molecular Sciences, 2018, 19, 3837.	4.1	139
32	Tumor immune evasion arises through loss of TNF sensitivity. Science Immunology, 2018, 3, .	11.9	244
33	Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. Frontiers in Immunology, 2018, 9, 70.	4.8	120
34	Bi-Allelic Mutations in STXBP2 Reveal a Complementary Role for STXBP1 in Cytotoxic Lymphocyte Killing. Frontiers in Immunology, 2018, 9, 529.	4.8	16
35	IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. Expert Opinion on Investigational Drugs, 2018, 27, 691-697.	4.1	12
36	CARs versus BiTEs: A Comparison between T Cellâ€"Redirection Strategies for Cancer Treatment. Cancer Discovery, 2018, 8, 924-934.	9.4	173

#	Article	IF	Citations
37	Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3â^' Cellâ€"Mediated Modulation of CD103+ Dendritic Cells. Cancer Immunology Research, 2018, 6, 1069-1081.	3.4	67
38	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nature Medicine, 2018, 24, 986-993.	30.7	689
39	A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. Cancer Research, 2017, 77, 1296-1309.	0.9	61
40	HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors. Cancer Research, 2017, 77, 2594-2606.	0.9	23
41	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Reports, 2017, 18, 2162-2174.	6.4	244
42	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. European Journal of Cancer, 2017, 81, 116-129.	2.8	443
43	Combined immune checkpoint blockade as a therapeutic strategy for <i>BRCA1</i> -mutated breast cancer. Science Translational Medicine, 2017, 9, .	12.4	227
44	A novel combination strategy for effectively targeting cancer stemâ€like cells. Immunology and Cell Biology, 2017, 95, 573-574.	2.3	3
45	CAR Tâ€cell therapy of solid tumors. Immunology and Cell Biology, 2017, 95, 356-363.	2.3	155
46	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. Clinical Cancer Research, 2017, 23, 2478-2490.	7.0	95
47	Combined CDK4/6 and PI3KÎ± Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. Cancer Research, 2017, 77, 6340-6352.	0.9	163
48	Neoadjuvant Interferons: Critical for Effective PD-1â€"Based Immunotherapy in TNBC. Cancer Immunology Research, 2017, 5, 871-884.	3.4	63
49	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nature Communications, 2017, 8, 606.	12.8	89
50	A Novel Target Antigen for the Treatment of Acute Myeloid Leukemia by CAR T Cells. Molecular Therapy, 2017, 25, 1997-1998.	8.2	2
51	CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature, 2017, 549, 101-105.	27.8	624
52	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. Journal of Clinical Investigation, 2017, 127, 929-941.	8.2	251
53	An ultrastructural investigation of tumors undergoing regression mediated by immunotherapy. Oncotarget, 2017, 8, 115215-115229.	1.8	6
54	Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing. OncoImmunology, 2016, 5, e1196308.	4.6	41

#	Article	IF	Citations
55	Immunosuppressive activities of adenosine in cancer. Current Opinion in Pharmacology, 2016, 29, 7-16.	3.5	216
56	The doubleâ€edged sword of IFNâ€Î³â€dependent immuneâ€based therapies. Immunology and Cell Biology, 2016, 94, 527-528.	2.3	7
57	Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer. OncoImmunology, 2016, 5, e1149667.	4.6	11
58	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nature Reviews Clinical Oncology, 2016, 13, 228-241.	27.6	679
59	Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Seminars in Immunology, 2016, 28, 64-72.	5.6	52
60	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clinical Cancer Research, 2016, 22, 1499-1509.	7.0	428
61	A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer. Oncotarget, 2016, 7, 34582-34598.	1.8	13
62	The Role of the immunological Synapse Formed by Cytotoxic Lymphocytes in Immunodeficiency and Anti-Tumor immunity. Critical Reviews in Immunology, 2015, 35, 325-347.	0.5	11
63	Expression of a Chimeric Antigen Receptor in Multiple Leukocyte Lineages in Transgenic Mice. PLoS ONE, 2015, 10, e0140543.	2.5	12
64	Adenosine Receptor 2A Blockade Increases the Efficacy of Antiâ€“PD-1 through Enhanced Antitumor T-cell Responses. Cancer Immunology Research, 2015, 3, 506-517.	3.4	262
65	Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. Molecular Immunology, 2015, 67, 46-57.	2.2	100
66	CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells. Cancer Immunology Research, 2015, 3, 483-494.	3.4	103
67	Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. Immunotherapy, 2015, 7, 499-512.	2.0	18
68	Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein. Clinical and Translational Immunology, 2015, 4, e30.	3.8	39
69	Releasing the Brake on Oncolytic Viral Therapy. Clinical Cancer Research, 2015, 21, 5417-5419.	7.0	3
70	Adoptive immunotherapy: a new era for the treatment of cancer. Immunotherapy, 2015, 7, 469-471.	2.0	4
71	Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Medicine, 2015, 13, 202.	5.5	177
72	CD73: A potential biomarker for anti-PD-1 therapy. OncoImmunology, 2015, 4, e1046675.	4.6	33

#	Article	IF	Citations
73	CAR-T cells are serial killers. OncoImmunology, 2015, 4, e1053684.	4.6	14
74	Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene. PLoS ONE, 2015, 10, e0136817.	2.5	14
75	Cross-talk between tumors can affect responses to therapy. OncoImmunology, 2015, 4, e975572.	4.6	7
76	The potential impact of mouse model selection in preclinical evaluation of cancer immunotherapy. OncoImmunology, 2014, 3, e946361.	4.6	6
77	Trafficking of T Cells into Tumors. Cancer Research, 2014, 74, 7168-7174.	0.9	313
78	Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors. OncoImmunology, 2014, 3, e963395.	4.6	8
79	Manipulating immune cells for adoptive immunotherapy of cancer. Current Opinion in Immunology, 2014, 27, 46-52.	5.5	46
80	Editorial overview: Tumour immunology: New frontiers in cancer immunotherapy. Current Opinion in Immunology, 2014, 27, vii-x.	5.5	0
81	Tissues in Different Anatomical Sites Can Sculpt and Vary the Tumor Microenvironment to Affect Responses to Therapy. Molecular Therapy, 2014, 22, 18-27.	8.2	112
82	Foxp3 expression in T regulatory cells and other cell lineages. Cancer Immunology, Immunotherapy, 2014, 63, 869-876.	4.2	74
83	Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. Leukemia Research, 2014, 38, 948-954.	0.8	14
84	Clinical application of genetically modified T cells in cancer therapy. Clinical and Translational Immunology, 2014, 3, e16.	3.8	94
85	Genetic Modification of Mouse Effector and Helper T Lymphocytes Expressing a Chimeric Antigen Receptor. Methods in Molecular Biology, 2014, 1139, 177-187.	0.9	2
86	Routes of Delivery for CpG and Anti-CD137 for the Treatment of Orthotopic Kidney Tumors in Mice. PLoS ONE, 2014, 9, e95847.	2.5	10
87	Foxp3 Expression in Macrophages Associated with RENCA Tumors in Mice. PLoS ONE, 2014, 9, e108670.	2.5	23
88	Gene-engineered T cells for cancer therapy. Nature Reviews Cancer, 2013, 13, 525-541.	28.4	425
89	Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor. Immunotherapy, 2013, 5, 577-590.	2.0	5
90	CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11091-11096.	7.1	406

#	Article	IF	Citations
91	Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia. Molecular Therapy, 2013, 21, 2122-2129.	8.2	361
92	A_{2A}blockade enhances anti-metastatic immune responses. OncoImmunology, 2013, 2, e26705.	4.6	17
93	Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. OncoImmunology, 2013, 2, e25962.	4.6	80
94	Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. OncoImmunology, 2013, 2, e26286.	4.6	108
95	Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. OncoImmunology, 2013, 2, e25961.	4.6	162
96	Blockade of A _{2A} receptors potently suppresses the metastasis of CD73 ⁺ tumors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14711-14716.	7.1	306
97	Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells. Clinical Cancer Research, 2013, 19, 5636-5646.	7.0	598
98	Environmental enrichment does not impact on tumor growth in mice. F1000Research, 2013, 2, 140.	1.6	18
99	Engineering T Cell Function Using Chimeric Antigen Receptors Identified Using a DNA Library Approach. PLoS ONE, 2013, 8, e63037.	2.5	44
100	Oncolytic Virus and Antiâ€"4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer. Cancer Research, 2012, 72, 1651-1660.	0.9	94
101	Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. OncoImmunology, 2012, 1, 1344-1354.	4.6	8
102	CD73-Deficient Mice Are Resistant to Carcinogenesis. Cancer Research, 2012, 72, 2190-2196.	0.9	178
103	CD73: a potent suppressor of antitumor immune responses. Trends in Immunology, 2012, 33, 231-237.	6.8	310
104	Autoimmunity associated with immunotherapy of cancer. Blood, 2011, 118, 499-509.	1.4	163
105	Activating and inhibitory receptors of natural killer cells. Immunology and Cell Biology, 2011, 89, 216-224.	2.3	426
106	Stable IL-10: A New Therapeutic that Promotes Tumor Immunity. Cancer Cell, 2011, 20, 691-693.	16.8	31
107	Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunology, Immunotherapy, 2011, 60, 671-683.	4.2	74
108	Alloreactive natural killer cells in hematopoietic stem cell transplantation. Leukemia Research, 2011, 35, 14-21.	0.8	21

#	Article	IF	Citations
109	Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy, 2011, 3, 33-48.	2.0	44
110	CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis. Cancer Research, 2011, 71, 2892-2900.	0.9	353
111	Autologous Peripheral Blood T Lymphocytes Transduced with An Anti LewisY Chimeric Receptor Gene Persist In Patients with Lewisy Positive Acute Myeloid Leukaemia and Show Changes In Functional Polarization After Adoptive Transfer,. Blood, 2011, 118, 4180-4180.	1.4	0
112	Characterizing the anti-tumor function of adoptively transferred NK cells in vivo. Cancer Immunology, Immunotherapy, 2010, 59, 1235-1246.	4.2	23
113	Multiple Antitumor Mechanisms Downstream of Prophylactic Regulatory T-Cell Depletion. Cancer Research, 2010, 70, 2665-2674.	0.9	67
114	CD11c+ Dendritic Cells and B Cells Contribute to the Tumoricidal Activity of Anti-DR5 Antibody Therapy in Established Tumors. Journal of Immunology, 2010, 185, 532-541.	0.8	49
115	Tumor Ablation by Gene-Modified T Cells in the Absence of Autoimmunity. Cancer Research, 2010, 70, 9591-9598.	0.9	49
116	Enhancing adoptive immunotherapy of cancer. Expert Opinion on Biological Therapy, 2010, 10, 531-545.	3.1	14
117	Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice. Journal of Translational Medicine, 2010, 8, 42.	4.4	24
118	Generation of Chimeric T-Cell Receptor Transgenes and Their Efficient Transfer in Primary Mouse T Lymphocytes. Methods in Molecular Biology, 2010, 651, 291-306.	0.9	1
119	Anti-Tumor Activity of Genetically Redirected T Cells Against Orthotopic Kidney Cancer in Mice~!2010-01-06~!2010-03-24~!2010-05-13~!. The Open Gene Therapy Journal, 2010, 3, 1-7.	1.2	0
120	Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice. Clinical Cancer Research, 2009, 15, 7624-7633.	7.0	22
121	cAMP Response Element Binding Protein Is Required for Mouse Neural Progenitor Cell Survival and Expansion. Stem Cells, 2009, 27, 1347-1357.	3.2	76
122	The Lewis-Y Carbohydrate Antigen is Expressed by Many Human Tumors and Can Serve as a Target for Genetically Redirected T cells Despite the Presence of Soluble Antigen in Serum. Journal of Immunotherapy, 2009, 32, 292-301.	2.4	56
123	Genetic modification of natural killer cells for adoptive cellular immunotherapy. Immunotherapy, 2009, 1, 623-630.	2.0	18
124	Bcl-2 Over-Expression and Genetic Manipulation of T Cells Provides Tumor Specificity and Enhanced Resistance to Apoptosis In Vitro. The Open Gene Therapy Journal, 2009, 2, 29-37.	1.2	0
125	Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer. Cancer Immunology, Immunotherapy, 2008, 57, 1635-1645.	4.2	33
126	IL-21 priming enhances T-cell immunotherapy. Blood, 2008, 111, 5268-5269.	1.4	1

#	Article	IF	Citations
127	Targeting Lewis Y-Positive Multiple Myeloma and Acute Myeloid Leukemia with Gene-Modified T Cells Demonstrating Memory Phenotype. Blood, 2008, 112, 3900-3900.	1.4	7
128	Sustained Antigen-Specific Antitumor Recall Response Mediated by Gene-Modified CD4+ T Helper-1 and CD8+ T Cells. Cancer Research, 2007, 67, 11428-11437.	0.9	59
129	Combined Natural Killer T-Cellâ€"Based Immunotherapy Eradicates Established Tumors in Mice. Cancer Research, 2007, 67, 7495-7504.	0.9	64
130	Perforin activity and immune homeostasis: the common A91V polymorphism in perforin results in both presynaptic and postsynaptic defects in function. Blood, 2007, 110, 1184-1190.	1.4	82
131	Adoptive Transfer of Chimeric Fc Îµ RI Receptor Gene-Modified Human T Cells for Cancer Immunotherapy. Human Gene Therapy, 2006, 17, 1134-1143.	2.7	23
132	Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood, 2005, 106, 2995-3003.	1.4	100
133	Supernatural T cells: genetic modification of T cells for cancer therapy. Nature Reviews Immunology, 2005, 5, 928-940.	22.7	137
134	Frizzled-7 receptor ectodomain expression in a colon cancer cell line induces morphological change and attenuates tumor growth. Differentiation, 2005, 73, 142-153.	1.9	52
135	T Cells Gene-engineered with DAP12 Mediate Effector Function in an NKG2D-dependent and Major Histocompatibility Complex-independent Manner. Journal of Biological Chemistry, 2005, 280, 38235-38241.	3.4	12
136	Colon Epithelial Cell Differentiation Is Inhibited by Constitutive c-Myb Expression or Mutant APC Plus Activated RAS. DNA and Cell Biology, 2005, 24, 21-29.	1.9	21
137	Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 19051-19056.	7.1	136
138	Gene Modification Strategies to Induce Tumor Immunity. Immunity, 2005, 22, 403-414.	14.3	56
139	A Network of PDZ-Containing Proteins Regulates T Cell Polarity and Morphology during Migration and Immunological Synapse Formation. Immunity, 2005, 22, 737-748.	14.3	237
140	Biochemical and growth regulatory activities of the HIN-200 family member and putative tumor suppressor protein, AIM2. Biochemical and Biophysical Research Communications, 2005, 326, 417-424.	2.1	41
141	Immunotherapy of Cancer Using Systemically Delivered Gene-Modified Human T Lymphocytes. Human Gene Therapy, 2004, 15, 699-708.	2.7	45
142	The Functional Basis for Hemophagocytic Lymphohistiocytosis in a Patient with Co-inherited Missense Mutations in the Perforin (PFN1) Gene. Journal of Experimental Medicine, 2004, 200, 811-816.	8.5	67
143	Gene-Engineered T Cells as a Superior Adjuvant Therapy for Metastatic Cancer. Journal of Immunology, 2004, 173, 2143-2150.	0.8	77
144	A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Therapy, 2004, 11, 371-379.	4.6	55

#	Article	IF	Citations
145	Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood, 2002, 100, 3155-3163.	1.4	165
146	Induction of tumor-specific T cell memory by NK cellâ€"mediated tumor rejection. Nature Immunology, 2002, 3, 83-90.	14.5	319
147	Identification and Characterization of a Novel Family of Mammalian Ependymin-Related Proteins (MERPs) in Hematopoietic, Nonhematopoietic, and Malignant Tissues. DNA and Cell Biology, 2001, 20, 625-635.	1.9	32
148	Redirecting Mouse CTL Against Colon Carcinoma: Superior Signaling Efficacy of Single-Chain Variable Domain Chimeras Containing TCR-Î¶ vs FcÎµRI-Î³. Journal of Immunology, 2001, 166, 182-187.	0.8	125
149	Redirected Perforin-Dependent Lysis of Colon Carcinoma by Ex Vivo Genetically Engineered CTL. Journal of Immunology, 2000, 164, 3705-3712.	0.8	79
150	Fas-ligand-mediated lysis of erbB-2-expressing tumour cells by redirected cytotoxic T lymphocytes. Cancer Immunology, Immunotherapy, 1999, 47, 278-286.	4.2	28
151	XENOSPECIFIC CD8+ CYTOTOXIC T LYMPHOCYTE GENERATION. Transplantation, 1998, 65, 1278-1281.	1.0	7
152	cDNA cloning of granzyme J. Immunogenetics, 1997, 45, 452-454.	2.4	5
153	Redirected Cytotoxic Effector Function. Journal of Biological Chemistry, 1996, 271, 21214-21220.	3.4	12